Trial Search Results

Pulmonary Fibrosis Foundation Patient Registry

The Pulmonary Fibrosis Foundation Patient Registry will collect data on at least 2,000 patients with interstitial lung disease (ILD) at approximately 40 clinical sites in the US. The Registry is targeting enrollment of approximately 60% of the 2,000 ILD participants to have idiopathic pulmonary fibrosis (IPF). The aim of the Registry is to create a cohort of well-characterized patients with interstitial lung disease (ILD) for participation in retrospective and prospective research

Stanford is currently accepting patients for this trial.

Lead Sponsor:

University of Michigan

Collaborator: Pulmonary Fibrosis Foundation

Stanford Investigator(s):


Inclusion Criteria:

   1. 18 years old or older

   2. Understand and sign the informed consent document

   3. ILD Diagnosis must be made / confirmed at a participating Registry center.

      1. The diagnostic evaluation must include, at a minimum, a medical history, physical
      examination, pulmonary function testing and a computerized tomography (CT) scan
      of the chest.

      2. If patients exhibit another pulmonary disease (such as emphysema or asthma), the
      primary disease must be ILD.

   4. Anticipated additional follow up at the Registry center within one year.

Exclusion Criteria:

1. Diagnosed with:

   1. Sarcoid

   2. Lymphangioleiomyomatosis (LAM)

   3. Pulmonary alveolar proteinosis (PAP)

   4. Cystic fibrosis (CF)

   5. Amyloidosis

Ages Eligible for Study

18 Years - 99 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305